Ganapati Mudur

Learn More
India’s Supreme Court began to hear final arguments this week in a long legal battle in which the drug company Novartis is challenging what patients’ groups have described as a key public health safeguard in India’s patent law. Novartis is challenging a decision by India’s patent office in 2006 to reject its patent for the anticancer drug imatinib mesilate(More)